By Rebecca Robbins Novo Nordisk will replace its chief executive, Lars Fruergaard Jorgensen, the company announced Friday, citing a sharp decline in its stock price that stemmed from increased ...

Novo Nordisk (NYSE: NVO) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market. As Reuters reports today, an online weight loss company ...

Despite Novo Nordisk's stock decline, the company's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases. Eli Lilly's oral weight-loss drug ...

Novo Nordisk announced Friday that it would part ways with its longtime CEO, who steered the company into an unprecedented boom time for weight-loss drugs. The Ozempic maker’s chief executive ...

Under Jorgensen's leadership, Novo Nordisk became a world leader in the lucrative weight-loss drug market, with sky-rocketing sales of its Wegovy and Ozempic treatments. Sign up here. "The changes ...

LONDON, May 16 (Reuters) - Wegovy-maker Novo Nordisk (NOVOb.CO), opens new tab said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover ...

Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen is stepping down after eight years in the role, during which he led the company to an all-time high in the markets. Despite being the first to ...

Mads Claus Rasmussen / Ritzau Scanpix / AFP / Getty Images U.S.-listed shares of Novo Nordisk (NVO) declined in the opening minutes of trading Friday on the surprise news that CEO Lars Fruergaard ...

May 16 (UPI) --Novo Nordisk announced Friday that CEO Lars Fruergaard Jorgensen is stepping down per mutual agreement with the company. The company said Friday that Jorgensen will continue as CEO ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will resign from the company after a short transition period. His replacement has not yet been found. Novo Nordisk stock is down 50% in 12 months ...